<DOC>
	<DOCNO>NCT02306096</DOCNO>
	<brief_summary>This study evaluate genomic profile breast cancer prospective population-based manner . In first phase , breast tumor analyze whole transcriptome RNA-sequencing . Gene expression profile , mutational profile , transcript isoform-level data analyze context patient information , clinicopathological variable , outcome , purpose develop new molecular diagnostic assay breast cancer . Additional genome-scale RNA , DNA , protein analysis perform future .</brief_summary>
	<brief_title>Sweden Cancerome Analysis Network - Breast : Genomic Profiling Breast Cancer</brief_title>
	<detailed_description>Breast cancer exhibit significant molecular , pathological , clinical heterogeneity . Current patient clinicopathological evaluation imperfect predict outcome , result overtreatment many patient , others , lead death recurrent disease . Therefore , additional criterion need well personalize care maximize treatment effectiveness survival . The Sweden Cancerome Analysis Network - Breast ( SCAN-B ) study initiated 2010 multicenter prospective population-based observational study longsighted aim analyze breast cancer next-generation genomic technology translational research integrate healthcare ; decipher fundamental tumor biology analysis ; utilize genomic data develop validate new clinically-actionable biomarker assay ; establish real-time clinical implementation molecular diagnostic , prognostic , predictive test . In first phase , focus molecular profile next-generation RNA-sequencing . Gene expression profile , mutational profile , transcript isoform-level data analyze context patient information , clinicopathological variable , outcome , purpose develop new molecular diagnostic assay breast cancer . Additional genome-scale RNA , DNA , protein analysis perform future . As January 2016 , 8000 patient enrol study , represent approximately 85 % eligible patient within catchment region . Tissue blood collection integrate within healthcare routine clinical information provide national quality registry .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>suspicion confirm diagnosis primary breast cancer sign inform consent lack sign informed consent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>prognostic predictive biomarkers</keyword>
	<keyword>RNA-sequencing</keyword>
	<keyword>pathological complete response</keyword>
	<keyword>minimal residual disease</keyword>
	<keyword>molecular subtype</keyword>
	<keyword>gene expression profile</keyword>
	<keyword>mutation screen</keyword>
	<keyword>BRCA</keyword>
	<keyword>translational research</keyword>
	<keyword>genomics</keyword>
	<keyword>transcriptomics</keyword>
	<keyword>proteomics</keyword>
	<keyword>metabolomics</keyword>
	<keyword>liquid biopsy</keyword>
	<keyword>circulate tumor cell</keyword>
	<keyword>circulate tumor DNA</keyword>
</DOC>